Form 4: Eledon Pharmaceuticals CEO Acquires 517,454 Shares Through Stock Option Vesting

Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, acquired 517,454 shares of common stock through the vesting of a stock option on June 13, 2024.

Summary

• David-Alexandre C. Gros, CEO of Eledon Pharmaceuticals, acquired 517,454 shares of common stock due to the attainment of performance conditions related to a stock option.
• The stock option, granted on May 1, 2023, had both performance-based and time-based vesting criteria.
• The performance-based vesting criteria for 517,454 shares were met on June 13, 2024.
• Time-based vesting criteria for 129,363 shares were met on May 1, 2024.
• The remaining 388,091 shares will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.
• The exercise price of the stock option is $2.30.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of stock options is a routine event, but the attainment of performance-based criteria suggests positive progress within the company.

Positives

• The CEO's acquisition of shares through option vesting could be seen as a positive signal, indicating confidence in the company's future performance.
• The vesting schedule provides ongoing incentive for the CEO over the next three years.

Future Outlook

The remaining 388,091 shares of the stock option will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Industry Context

Stock option grants and vesting are common practices in the pharmaceutical industry to incentivize and retain key executives. The vesting terms, including performance-based criteria, are designed to align management's interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options with vesting schedules tied to performance and time-based milestones.
• The specific terms of the vesting schedule, such as the performance metrics and vesting period, vary depending on the company's size, stage of development, and strategic goals.

Stakeholder Impact

• The vesting of stock options could have a minor dilutive effect on existing shareholders.
• The vesting incentivizes the CEO to continue driving company performance, which could benefit shareholders, employees, and other stakeholders.

Key Dates